Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

News Conference News ACC 2024

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

L.A. McKeown

April 08, 2024

Presentation ACC 2024

PREVENT: Preventive PCI versus Medical Therapy Alone for Treatment of Vulnerable Atherosclerotic Coronary Plaques

Presenter: Seung-Jung Park

April 07, 2024

News Conference News ACC 2023

No Downside to Immediate Complete Revascularization in ACS: BIOVASC

Michael O'Riordan

March 06, 2023

Presentation ACC 2023

Effect of Evolocumab on Coronary Plaque Characteristics in Stable Coronary Artery Disease: a Multimodality Imaging Study (YELLOW III)

Presenter: Annapoorna S. Kini

March 06, 2023

Presentation ACC 2023

Complete Revascularization Strategies in Patients Presenting With Acute Coronary Syndrome and Multivessel Coronary Disease

Presenter: Roberto Diletti

March 05, 2023

News Conference News ACC 2023

Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III

Shelley Wood

March 04, 2023

News Conference News ACC 2022

FLAVOUR: FFR as Good as IVUS for Intermediate Coronary Stenoses

Michael O'Riordan

April 06, 2022

Presentation ACC 2022

Comparison Of Fractional Flow Reserve-guided And Intravascular Ultrasound-guided Percutaneous Coronary Intervention In Intermediate Coronary Artery Stenosis: The FLAVOUR Randomized Clinical Trial

Presenter: Bon-Kwon Koo

April 04, 2022

News Conference News ACC 2022

PACMAN-AMI: Positive Plaque Changes With Early Alirocumab Use in Acute MI

Todd Neale

April 03, 2022

News Conference News ACC 2020

PCI Equal to Surgery in Left Main CAD: PRECOMBAT at 10 Years

Michael O'Riordan

March 30, 2020

News Conference News ACC 2019

High Rate of Residual Ischemia After PCI Despite Excellent Angiographic Outcomes: DEFINE-PCI

Michael O'Riordan

March 21, 2019

Advertisement

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

PREVENT: Preventive PCI versus Medical Therapy Alone for Treatment of Vulnerable Atherosclerotic Coronary Plaques

No Downside to Immediate Complete Revascularization in ACS: BIOVASC

Effect of Evolocumab on Coronary Plaque Characteristics in Stable Coronary Artery Disease: a Multimodality Imaging Study (YELLOW III)

Complete Revascularization Strategies in Patients Presenting With Acute Coronary Syndrome and Multivessel Coronary Disease

Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III

FLAVOUR: FFR as Good as IVUS for Intermediate Coronary Stenoses

Comparison Of Fractional Flow Reserve-guided And Intravascular Ultrasound-guided Percutaneous Coronary Intervention In Intermediate Coronary Artery Stenosis: The FLAVOUR Randomized Clinical Trial

PACMAN-AMI: Positive Plaque Changes With Early Alirocumab Use in Acute MI

PCI Equal to Surgery in Left Main CAD: PRECOMBAT at 10 Years

High Rate of Residual Ischemia After PCI Despite Excellent Angiographic Outcomes: DEFINE-PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content